News
State Street Global Advisors Research Examines Investors’ Risk Awareness Amid Market Volatility
State Street Global Advisors, the asset management business of State Street Corporation (NYSE: STT), today released its ETFs in Focus Study: Risk Management Attitudes & Behaviors and its ETF Impact
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 2025
Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2025.
Since the beginning of the year, the Group has recorded a consolidated revenues amounting
GE HealthCare unveils ultra-premium, high-performance gradient 1.5T MRI system
GE HealthCare (Nasdaq: GEHC) today unveiled SIGNA™ Sprint, an FDA 510(k) pending1 ultra-premium wide bore 1.5T high-performance gradient MRI system, at the International Society for Magnetic
Redfin Reports U.S. Asking Rents Fell 1% Year Over Year in April—Biggest Drop in 14 Months
(NASDAQ: RDFN) — The median U.S. asking rent fell 1% year over year to $1,625 in April, marking the biggest decline since February 2024, according to a new report from Redfin (redfin.com), the
Hardman & Co publication on NB Private Equity Partners: 2024 - short-term noise over long-term growth
Chewy CFO David Reeder to Depart Chewy, Company Reaffirms First Quarter Guidance
Chewy, Inc. (NYSE: CHWY), a trusted destination for pet parents and partners everywhere, announced today that the Company’s Chief Financial Officer, David Reeder, will be departing in several
Northisle Commences Trading on the OTCQX Market Under the Symbol NTCPF
Northisle Copper and Gold Inc. (TSX-V: NCX) (“Northisle” or the “Company”) is pleased to announce that, effective today, the Company’s common shares will commence trading on the OTCQX® Best Market
Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2025.
First Quarter 2025 Financial Results
-
Total Revenue: For the three
Dole plc Reports First Quarter 2025 Financial Results
Dole plc (NYSE: DOLE) ("Dole" or the "Group" or the "Company") today released its financial results for the three months ended March 31, 2025.
Highlights for the three months ended March 31,
EQS-News: Porsche AG continues generational change to its Executive Board
EQS-News: North Peak Announces Harry Dobson Has Been Appointed Executive Chairman and a Director; Grant of Stock Options
German Firms Move to Cloud-Based SAP for Speed, Agility
Accelerated cloud adoption is reshaping the SAP ecosystem in Germany as enterprises shift toward the company’s cloud-based solutions despite ongoing concerns, according to a new research report
EQS-News: Franz-Josef Wiese appointed to the Supervisory Board of EnviTec Biogas AG
Hoffmann Green Cement and Norske Skog Golbey Transform Paper Ash and Recycle It Into Resources for the Manufacture of 0% Clinker Cement
Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector
EQS-News: Shelly Group: Invitation to unaudited 3M 2025 earnings webcast/call on 15 May 2025
Cairn Homes Plc: Holding(s) in Company
EQS-News: Share Buyback
Funding Circle Holdings plc: HOL-Holding(s) in Company
Cairn Homes Plc: Director/PDMR Shareholding
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to



